Public Health Clinical Center Affiliated to Fudan University
Welcome,         Profile    Billing    Logout  
 11 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Liang
HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting
4
640
RoW
Tenofovir Amibufenamide（TMF）, HS-10234
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
06/24
09/29
NCT06092684: The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery

Completed
3
358
RoW
BT-KTM-I, Esketamine, Ketanest®S
Chengdu Brilliant Pharmaceutical Co., Ltd.
Laparoscopy, Anesthesia, Intravenous
03/24
03/24
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Completed
2
250
RoW
GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table
Sunshine Lake Pharma Co., Ltd.
Chronic HBV Infection
06/22
09/23
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Recruiting
2
88
RoW
RC88, RC88 for Injection
RemeGen Co., Ltd.
Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer
06/26
12/26
NCT06353360: TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

Recruiting
2
30
RoW
Tumor Treating Fields, Tislelizumab, Temozolomide (TMZ)
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Glioblastoma Multiforme
07/25
03/26
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting
2
90
RoW
B013, Paclitaxel, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Platinum-resistant Recurrent Ovarian Cancer
12/26
12/26
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recruiting
1/2
54
RoW
Bevacizumab； HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Recurrent Ovarian Cancer
10/25
10/25
TRUE, NCT03752658: TAF Real World Study for Universal Effectiveness

Recruiting
N/A
500
RoW
Tenofovir Alafenamide, Vemlidy®
Tongji Hospital, Gilead Sciences
Chronic Hepatitis b
05/23
09/23
TRIPHY, NCT06480890: Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients

Active, not recruiting
N/A
359
RoW
Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
10/25
10/25
NCT05920174: Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Neural Acquisitor & Stimulator System in Patients With Motor Disability

Recruiting
N/A
9
RoW
NEO
Neuracle Medical Technology(Shanghai) Co.,Ltd., Xuanwu Hospital, Beijing, Beijing Tiantan Hospital, Chinese PLA General Hospital, Huashan Hospital
Tetraplegia
12/24
12/25
SPEED, NCT06862206: This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Not yet recruiting
N/A
1000
RoW
benralizumab
AstraZeneca
Chronic Obstructive Pulmonary Disease
01/26
01/26
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C

Recruiting
N/A
300
RoW
Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir
Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd
Hepatitis C, Chronic
07/21
08/21
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Liang
HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

Active, not recruiting
4
640
RoW
Tenofovir Amibufenamide（TMF）, HS-10234
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
06/24
09/29
NCT06092684: The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery

Completed
3
358
RoW
BT-KTM-I, Esketamine, Ketanest®S
Chengdu Brilliant Pharmaceutical Co., Ltd.
Laparoscopy, Anesthesia, Intravenous
03/24
03/24
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Completed
2
250
RoW
GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table
Sunshine Lake Pharma Co., Ltd.
Chronic HBV Infection
06/22
09/23
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Recruiting
2
88
RoW
RC88, RC88 for Injection
RemeGen Co., Ltd.
Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer
06/26
12/26
NCT06353360: TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

Recruiting
2
30
RoW
Tumor Treating Fields, Tislelizumab, Temozolomide (TMZ)
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Glioblastoma Multiforme
07/25
03/26
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Recruiting
2
90
RoW
B013, Paclitaxel, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Platinum-resistant Recurrent Ovarian Cancer
12/26
12/26
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
NCT06308406: A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Recruiting
1/2
54
RoW
Bevacizumab； HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Recurrent Ovarian Cancer
10/25
10/25
TRUE, NCT03752658: TAF Real World Study for Universal Effectiveness

Recruiting
N/A
500
RoW
Tenofovir Alafenamide, Vemlidy®
Tongji Hospital, Gilead Sciences
Chronic Hepatitis b
05/23
09/23
TRIPHY, NCT06480890: Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients

Active, not recruiting
N/A
359
RoW
Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
10/25
10/25
NCT05920174: Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Neural Acquisitor & Stimulator System in Patients With Motor Disability

Recruiting
N/A
9
RoW
NEO
Neuracle Medical Technology(Shanghai) Co.,Ltd., Xuanwu Hospital, Beijing, Beijing Tiantan Hospital, Chinese PLA General Hospital, Huashan Hospital
Tetraplegia
12/24
12/25
SPEED, NCT06862206: This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Not yet recruiting
N/A
1000
RoW
benralizumab
AstraZeneca
Chronic Obstructive Pulmonary Disease
01/26
01/26
C-DIAMOND, NCT04952207: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C

Recruiting
N/A
300
RoW
Direct-acting antiviral agents, daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir, sofosbuvir, velpatasvir, ledipasvir, elbasvir, grazoprevir, danoprevir, glecaprevir, pibrentasvir, voxilaprevir
Qing XIe, Gilead Sciences, Tigermed Consulting Co., Ltd
Hepatitis C, Chronic
07/21
08/21

Download Options